Stoke Therapeutics (NASDAQ:STOK) Shares Up 6% - Still a Buy?

Key Points

• Shares rose about 6% to $37.60 on Monday with volume around 124,535 (down ~83% versus the average), valuing the company at roughly $2.15 billion and implying a P/E near 56.
• Analysts are broadly positive with a consensus rating of "Moderate Buy" and an average price target of $39.25, while individual targets range from $35 up to $60.
• Several large institutions (e.g., RTW, Morgan Stanley, Vanguard, State Street) have recently increased positions, and Stoke is a clinical‑stage biotech whose lead program, STK‑001, targets Dravet syndrome using its TANGO antisense platform.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s share price was up 6% on Monday . The company traded as high as $37.62 and last traded at $37.60. Approximately 124,535 shares traded hands during trading, a decline of 83% from the average daily volume of 720,591 shares. The stock had previously closed at $35.48.

Analyst Ratings Changes

Several equities analysts recently commented on STOK shares. Wolfe Research assumed coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They set an "outperform" rating and a $40.00 price target on the stock. UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research note on Monday, December 15th. Loop Capital set a $35.00 target price on shares of Stoke Therapeutics in a research note on Monday, January 5th. HC Wainwright lifted their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a "buy" rating in a research note on Monday, December 15th. Finally, Guggenheim assumed coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They issued a "buy" rating and a $60.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $39.25.

Stoke Therapeutics Stock Up 5.9%

The company has a 50 day simple moving average of $32.19 and a 200-day simple moving average of $29.09. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of 56.06 and a beta of 1.07.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. RTW Investments LP boosted its stake in Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company's stock valued at $176,057,000 after acquiring an additional 423,331 shares during the period. Morgan Stanley raised its position in shares of Stoke Therapeutics by 0.3% during the 4th quarter. Morgan Stanley now owns 3,546,158 shares of the company's stock worth $112,555,000 after purchasing an additional 9,108 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Stoke Therapeutics by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company's stock worth $74,351,000 after purchasing an additional 217,616 shares during the last quarter. State Street Corp boosted its position in Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company's stock valued at $79,288,000 after purchasing an additional 1,072,176 shares during the period. Finally, Marshall Wace LLP increased its position in Stoke Therapeutics by 7.9% in the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company's stock worth $26,111,000 after buying an additional 168,771 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.